Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00040
|
|||||
| Drug Name |
Amantadine
|
|||||
| Synonyms |
1-Adamantamine; 1-Adamantanamine; 1-Adamantanamine (8CI); 1-Adamantylamine; 1-Aminoadamantane; 1-Aminotricyclo(3.3.1.1(sup 3,7))decane; ADAMANTANE,1-AMINO; Adamantamine; Adamantan-1-amine; Adamantan-1-ylamine; Adamantanamine; Adamantylamine; Amant; Amantadina; Amantadina [INN-Spanish]; Amantadine (INN); Amantadine Base; Amantadine [INN:BAN]; Amantadinum; Amantadinum [INN-Latin]; Amantidine; Aminoadamantane; BIA4304; Endantadine; Gen-Amantadine; Mantadine; OR14310; Pk-merz; Symadine; Symmetrel; Symmetrel (TN); TCMDC-125869; Tricyclo(3.3.1.1(3,7))-decan-1-amine; Tricyclo(3.3.1.1(sup 3,7))decan-1-amine; Tricyclo(3.3.1.1(sup 3.7))decan-1-amine; Tricyclo(3.3.1.13,7)decan-1-amine; Tricyclo[3.3.1.1(3,7)]decan-1-amine;Tricyclo[3.3.1.1(3,7)]decan-1-ylamine; Tricyclo[3.3.1.1(3,7)]decane-1-amine; Tricyclo[3.3.1.1(sup3,7)]decan-1-amine; Tricyclo[3.3.1.1^3,7]decan-1-amine; Tricyclo[3.3.1.1~3,7~]decan-1-amine; Wiregyt
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Influenza A infection [ICD11: 1.00E+31] | Approved | [1] | |||
| Therapeutic Class |
Antiviral Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C10H17N
|
|||||
| Canonical SMILES |
C1C2CC3CC1CC(C2)(C3)N
|
|||||
| InChI |
InChI=1S/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H2
|
|||||
| InChIKey |
DKNWSYNQZKUICI-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 768-94-5
|
|||||
| Pharmaceutical Properties | Molecular Weight | 151.25 | Topological Polar Surface Area | 26 | ||
| Heavy Atom Count | 11 | Rotatable Bond Count | 0 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 1 | |||
| XLogP |
2.4
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10535392
, 11110715
, 11335990
, 11361229
, 11362804
, 11365366
, 11367928
, 11371422
, 11373687
, 11376090
, 11448576
, 11462201
, 11466435
, 11467555
, 11483738
, 11486009
, 11487897
, 11490107
, 11491949
, 11493844
, 15170902
, 15219251
, 16666659
, 24848359
, 26755640
, 26755641
, 29221309
, 30400536
, 3136147
, 38395099
, 461565
, 46168239
, 46507081
, 47216816
, 47216817
, 47440544
, 47515356
, 47589230
, 47736526
, 47959791
, 48035167
, 48035168
, 48259495
, 5106490
, 588114
, 597379
, 7978680
, 8147192
, 8151445
, 9036
|
|||||
| ChEBI ID |
ChEBI:2618
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | OCT-2 | Transporter Info | Organic cation transporter 2 | Substrate | [2] | |
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | OCT-2 | Transporter Info | Km = 27 microM | Human embryonic kidney cells (HEK293)-OCT2 | [2] | |
| OCT-2 | Transporter Info | Km = 27 microM | Oocytes-OCT2 | [2] | ||
| References | ||||||
| 1 | Amantadine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol. 1998 Aug;54(2):342-52. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.